Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.31 |
| ▸ | POLQ | O75417 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | CCR1 | P32246 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26251001 | 0.84 | POLB (0.40) | TSHRGAAALDH1A1HTTKDM4E | |
| SCHEMBL21420046 | 0.84 | POLB (0.40) | TSHRGAAALDH1A1HTTKDM4E | |
| SCHEMBL14487702 | 0.84 | POLB (0.40) | TSHRGAAALDH1A1HTTKDM4E | |
| SCHEMBL20832318 | 0.83 | PDE2A (0.33) | LMNATSHRNPSR1 | |
| SCHEMBL15730153 | 0.78 | MAPK8 (0.32) | LMNA | |
| SCHEMBL14487939 | 0.78 | LMNA (0.47) | LMNATSHRNPSR1GAAALDH1A1 | |
| SCHEMBL14555879 | 0.78 | LMNA (0.47) | LMNATSHRNPSR1GAAALDH1A1 | |
| SCHEMBL14487851 | 0.74 | LMNA (0.52) | LMNATSHRNPSR1GAAALDH1A1 | |
| SCHEMBL22002215 | 0.73 | LMNA (0.45) | LMNATSHRNPSR1GAAALDH1A1 | |
| SCHEMBL20078963 | 0.72 | LMNA (0.44) | LMNATSHRNPSR1GAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12636279-B2 | Choline salt forms of an HIV capsid inhibitor | GILEAD SCIENCES, INC. (US) | 2026-05-26 | — | — | US | disclosed |
| US-12594267-B2 | Capsid inhibitors for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2026-04-07 | — | — | US | disclosed |
| US-12492189-B2 | Solid forms of an HIV capsid inhibitor | GILEAD SCIENCES, INC. (US) | 2025-12-09 | — | — | US | disclosed |
| US-20240376077-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2024-11-14 | — | — | US | disclosed |
| EP-4458415-A2 | SOLID FORMS OF AN HIV CAPSID INHIBITOR | Gilead Sciences, Inc. (US) | 2024-11-06 | — | — | EP | disclosed |
| US-20240316018-A1 | CAPSID INHIBITORS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2024-09-26 | — | — | US | disclosed |
| US-20240254104-A1 | SOLID FORMS OF AN HIV CAPSID INHIBITOR | GILEAD SCIENCES, INC. | 2024-08-01 | — | — | US | disclosed |
| US-20240245669-A1 | Choline Salt Forms of an HIV Capsid Inhibitor | GILEAD SCIENCES, INC. | 2024-07-25 | — | — | US | disclosed |
| EP-4092020-B1 | SOLID FORMS OF AN HIV CAPSID INHIBITOR | GILEAD SCIENCES INC (US) | 2024-07-10 | — | — | EP | disclosed |
| EP-4092020-B1 | SOLID FORMS OF AN HIV CAPSID INHIBITOR | GILEAD SCIENCES INC (US) | 2024-07-10 | — | — | EP | disclosed |
| US-20170137405-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2017-05-18 | — | — | US | disclosed |
| US-9540343-B2 | Compounds for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2017-01-10 | — | — | US | disclosed |
| US-9540343-B2 | Compounds for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2017-01-10 | — | — | US | disclosed |
| US-9540343-B2 | Compounds for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2017-01-10 | — | — | US | disclosed |
| EP-2729448-B1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES INC (US) | 2015-09-09 | — | — | EP | disclosed |
| EP-2729448-B1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES INC (US) | 2015-09-09 | — | — | EP | disclosed |
| US-20140142085-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| US-20140142085-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| US-20140142085-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| WO-2013006738-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. (US) | 2013-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240316018-A1 | CAPSID INHIBITORS FOR THE TREATMENT OF HIV | SAP18, SLC11A2, CD4 | LMNA 2963/4885TSHR 4875/4885NPSR1 4596/4885 |
| US-12636279-B2 | Choline salt forms of an HIV capsid inhibitor | CHKA, SLC5A7, SLC44A1 | LMNA 2172/4885TSHR 4699/4885NPSR1 4544/4885 |
| US-12594267-B2 | Capsid inhibitors for the treatment of HIV | CTDSP1, POLR2H, POLR2E | LMNA 2900/4885TSHR 4800/4885NPSR1 4711/4885 |
| US-20240254104-A1 | SOLID FORMS OF AN HIV CAPSID INHIBITOR | ZC3HAV1, GTF3C3, ZC3HAV1L | LMNA 3763/4885TSHR 4139/4885NPSR1 4698/4885 |
| US-12492189-B2 | Solid forms of an HIV capsid inhibitor | ZC3HAV1, GTF3C3, ZC3HAV1L | LMNA 3763/4885TSHR 4139/4885NPSR1 4698/4885 |
| US-20240376077-A1 | THERAPEUTIC COMPOUNDS | HAVCR2, MAVS, EIF2AK2 | LMNA 4352/4885TSHR 4787/4885NPSR1 4064/4885 |
| US-20240245669-A1 | Choline Salt Forms of an HIV Capsid Inhibitor | CHKA, SLC44A1, SLC5A7 | LMNA 3156/4885TSHR 4762/4885NPSR1 4624/4885 |
| US-20170137405-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | CCR5, NPC1, FURIN | LMNA 3182/4885TSHR 4824/4885NPSR1 2832/4885 |
| US-20140142085-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | CCR5, NPC1, FURIN | LMNA 3182/4885TSHR 4824/4885NPSR1 2832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.